Phenotype-rescue of cyclin-dependent kinase inhibitor p16/INK4A defects in a spontaneous canine cell model of breast cancer

Journal of Cellular Biochemistry

Volumn 106, Issue 3, 2009, Pages 491-505

  Deinnocentes, Patricia ^a   Agarwal, Payal ^a   Bird, R Curtis ^a  

^a AUBURN UNIVERSITY   (United States)

Author keywords

CANINE; CDK; CELL CYCLE; CKI; MAMMARY CANCER

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE PHASE; CELL GROWTH; CELL PROLIFERATION; CELL STRUCTURE; CONTACT INHIBITION; CONTROLLED STUDY; DOG; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; ANIMAL; BREAST TUMOR; DISEASE MODEL; ENZYME SPECIFICITY; GENE EXPRESSION REGULATION; GENETICS; KINETICS; METABOLISM; MOLECULAR GENETICS; PHYLOGENY; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY; TRANSGENE; TUMOR CELL LINE;

ANIMALIA; CANIS FAMILIARIS;

ANIMALS; BASE SEQUENCE; BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE MODELS, ANIMAL; DOGS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KINETICS; MOLECULAR SEQUENCE DATA; PHENOTYPE; PHYLOGENY; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, NUCLEIC ACID; SUBSTRATE SPECIFICITY; TRANSGENES;

EID: 62649148957     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22034     Document Type: Article

References (50)

1. Ahem TE, Bird RC, Church Bird AE, Wolfe LG. 1996. Overexpression of the oncogene c-erbB-2 in canine mammary carcinomas and tumor-derived cell lines. Am J Vet Res 57:693-696.
2. Arellano M, Moreno S. 1997. Regulation of CDK/cyclin complexes during the cell cycle. Int J Biochem Cell Biol 29:559-573.
3. Bird RC. 1997. The cyclin/cyclin-dependent kinase (cdk) complex: Regulation of cell cycle progression and nuclear disassembly. In: Bird RC, Stein GS, Lian JB, Stein JL, editors. Nuclear structure and gene expression. San Diego: Academic Press, pp 145-174.
4. Bird RC. 2003. Regulation of cyclin-dependent kinase 1 (cdc2) expression during the G0/G1 phase transition and the consequences for regulation of cell cycle progression. In: Boonstra J, editor. G1 phase progression. Georgetown: Landes Biosciences, pp 1-18.
5. cdc2) Promoter. Anticancer Res 24:1469-1480.
6. Bird RC, Delnnocentes P, Lenz S, Thacker EE, Curiel DT, Smith BF. 2008. Cross-presentation of a hybrid-cell fusion vaccine against canine mammary cancer. Vet Immunol Immunopathol 123:289-304.
7. Bird RC. 2008. Defects in genes regulating the cell cycle in spontaneous canine models of cancer. In: Yoshida K, editor. Trends in cell cycle research. Kerala: Research Sign Post (in press).
8. Bostrom J, Meyer-Puttlitz B, Wolter M, Blaschke B, Weber RG, Lichter P, Ichimura K, Collins VP, Reifenberger G. 2001. Alterations of the tumor suppressor genes CDKN2A (pl6(INK4a)), pl4(ARF), CDKN2B (pl5(INK4b)), and CDKN2C (pl8(INK4c)) in atypical and anaplastic meningiomas. Am J Pathol 159:661-669.
9. Carnero A, Hudson JD, Price CM, Beach DH. 2000. p 16INK4A and p 19ARF act in overlapping pathways in cellular immortalization. Nat Cell Biol 2:148-155.
10. Cheng T, Scadden DT. 2002. Cell cycle entry of hematopoietic stem and progenitor cells controlled by distinct cyclin-dependent kinase inhibitors. Int J Hematol 75:460-465.
11. Christopher SA, Diegelman P, Porter CW, Kruger WD. 2002. Methylthioa-denosine phosphorylase, a gene frequently codeleted with p16(cdkN2a/ARF), acts as a tumor suppressor in a breast cancer cell line. Cancer Res 62:6639-6644.
12. Delnnocentes P, Li LX, Sanchez RL, Bird RC. 2006. Expression and sequence of canine SIRT2 and p53 alleles in canine mammary tumor cells-Effects on down stream targets Wip1 and p21/Cipl. Vet Comp Oncol 4:161-177.
13. Ekholm SV, Reed SI. 2000. Regulation of G(1) cyclin-dependent kinases in the mammalian cell cycle. Curr Opin Cell Biol 12:676-684.
14. Forsburg SL, Nurse P. 1991. Cell cycle regulation in the yeasts Saccharomyces cerevisiae and Schizosaccharomyces pombe. Annu Rev Cell Biol 7:227-256.
15. Frey RS, Li J, Singletary KW. 2001. Effects of genistein on cell proliferation and cell cycle arrest in nonneoplastic human mammary epithelial cells: Involvement of Cdc2, p21waf/cipl, p27kip1, and Cdc25C expression. Biochem Pharmacol 61:979-989.
16. Hamburger AW, Salmon SE. 1977. Primary bioassay of human tumor stem cells. Science 197:461-463.
17. Jeffrey PD, Tong L, Pavletich NP. 2000. Structural basis of inhibition of CDK-cyclin complexes by 1NK4 inhibitors. Genes Dev 14:3115-3125.
18. Khanna C, Lindblad-Toh K, Vail D, London C, Bergman P, Barber L, Breen M, Kitchell B, McNeil E, Modiano JF, Niemi S, Comstock KE, Ostrander E, Westmoreland S, Withrow S. 2006. The dog as a cancer model. Nat Biotechnol 24:1065-1066.
19. Koenig A, Bianco SR, Fosmire S, Wojcieszyn J, Modiano JF. 2002. Expression and Significance of p53, Rb, p21/waf-l, pl6/ink-4a, and PTEN Tumor Suppressors in Canine Melanoma. Vet Pathol 39:458-472.
20. LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, Fattaey A, Harlow E. 1997. New functional activities for the p21 family of CDK inhibitors. Genes Dev 11:847-862.
21. Levine AJ. 1997. p53 the cellular gatekeeper for growth and division. Cell 88:323-331.
22. Little JB, Nagasawa H, Keng PC, Yu Y, Li CY. 1995. Absence of radiation- induced G1 arrest in two closely related human lymphoblast cell lines that differ in p53 status. J Biol Chem 270:11033-11036.
23. Liu H, Bird RC. 1998. Characterization of the enhancer-like okadaic acid response element region of the cyclin-dependent kinase 1 (p34cdc2) promoter. Biochem Biophys Res Commun 246:696-702.
24. MacEwen EG, Withrow SJ. 1996. Tumors of the mammary gland. In: Withrow SJ, MacEwen EG, editors. Small animal oncology. Philadelphia: Saunder Co. pp 356-372.
25. Malek NP, Sundberg H, McGrew S, Nakayama K, Kyriakides TR, Roberts JM. 2001. A mouse knock-in model exposes sequential proteolytic pathways that regulate p27Kipl in Gl and S phase. Nature 413:323-327.
26. Malumbres M, Perez De Castro I, Hernandez MI, Jimenez M, Corral T, Pellicer A. 2000. Cellular response to oncogenic ras involves induction of the Cdk4 and Cdk6 inhibitor p 15(INK4b). Mol Cell Biol 20:2915-2925.
27. Medema RH, Herrera RE, Lam F, Weinberg RA. 1995. Growth suppression by p161NK4A requires functional retinoblastoma protein. Proc Natl Acad Sci USA 92:6289-6293.
28. Migone F, Bird RC, Delnnocentes P, Lenz S, Smith B. 2006. Alterations in CDK1 expression and localization following induction in a spontaneous canine mammary cancer model. J Cell Biochem 98:504-518.
29. Miyoshi N, Tateyama S, Ogawa K, Yamaguchi R, Kuroda H, Yasuda N, Shimizu T. 1991. Abnormal structure of the canine oncogene, related to the human c-yes-1 oncogene, in canine mammary tumor tissue. Am J Vet Res 52:2046-2049.
30. Nakayama K, Nakayama K. 1998. Cip/Kip cyclin-dependent kinase inhibitors: Brakes of the cell cycle engine during development. Bioessays 20:1020-1029.
31. Ritt MG, Mayor J, Wojcieszyn J, Smith R, Barton CL, Modiano JF. 2000. Sustained nuclear localization of p21 /WAF-1 upon growth arrest induced by contact inhibition. Cancer Lett 158:73-84.
32. Sandhu C, Peehl DM, Slingerland J. 2000. p161NK4A mediates cyclin dependent kinase 4 and 6 inhibition in senescent prostatic epithelial cells. Cancer Res 60:2616-2622.
33. Sartin EA, Barnes S, Toivio-Kinnucan M, Wright JC, Wolfe LG. 1993. Heterogenic properties of clonal cell lines derived from canine mammary carcinomas and sensitivity to tamoxifen and doxorubicin. Anticancer Res 13:229-236.
34. Sherr CJ, Roberts JM. 1999. CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev 13:1501-1512.
35. Pavletich NP. 1999. Mechanisms of cyclin-dependent kinase regulation: Structures of Cdks, their cyclin activators, and Cip and 1NK4 inhibitors. J Mol Biol 287:821-828.
36. Ruas M, Peters G. 1998. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1378:F115-F177.
37. Rungsipipat A, Tateyama S, Yamaguchi R, Uchida K, Murakami Y, Miyoshi N, Hayashi T. 1999. Amplification of the c-yes oncogene in canine mammary tumors. J Vet Med Sci 61:185-189.
38. Russo AA, Tong L, Lee J-0, Jeffrey PD, Pavletich NP. 1998. Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumor suppressor pl6INK4a. Nature 395:237-243.
39. Sandhu C, Slingerland J. 2000. Deregulation of the cell cycle in cancer. Cancer Detect Prev 24:107-118.
40. Schafer KA. 1998. The cell cycle: A review. Vet Pathol 35:461-478.
41. Sharpless NE, DePinho RA. 1999. The INK4A/ARF locus and its two gene products. Curr Opin Genet Dev 9:22-30.
42. Tyner AL, Gartel AL. 2003. Roles of cyclin kinase inhibitors in G1 phase progression. In: Boonstra J, editor. Gl phase progression. Georgetown: Landes Biosciences, pp 40-57.
43. Smits VA, Klompmaker R, Vallenius T, Rijksen G, Mäkela TP, Medema RH. 2000. p21 inhibits Thrl61 phosphorylation of Cdc2 to enforce the G2 DNA damage checkpoint. J Biol Chem 275:30638-30643.
44. Waldman T, Kinzler KW, Vogelstein B. 1995. p21 is necessary for the p53- mediated Gl arrest in human cancer cells. Cancer Res 55:5187-5190.
45. Wei W, Hemmer RM, Sedivy JM. 2001. Role of p14(ARF) in replicative and induced senescence of human fibroblasts. Mol Cell Biol 21:6748-6757.
46. Wolfe LG, Buxton-Smith B, Toivio-Kinnucan MA, Sartin EA, Kwapien RP, Henderson RA, Barnes S. 1986. Biologic properties of cell lines derived from canine mammary carcinomas. J Natl Cancer Inst 77:783-792.
47. Wolfel T, Hauer M, Schneider J, Schneider J, Serrano M, Wolfel C, Klehmann-Hieb E, De Plaen E, Hankeln T, Meyer zum Büschenfelde KH, Beach D. 1995. A p 16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269:1281-1284.
48. Yao SL, Akhtar AJ, McKenna KA, Bedi GC, Sidransky D, Mabry M, Ravi R, Collector MI, Jones RJ, Sharkis SJ, Fuchs EJ, Bedi A. 1996. Selective radio- sensitization of p53-deficient cells by caffeine-mediated activation of p34cdc2 kinase. Nat Med 2:1140-1143.
49. You J, Bird RC. 1995. Selective induction of cell cycle regulatory genes cdk1 (p34cdc2), cyclins A/B, and the tumor suppressor gene Rb in transformed cells by okadaic acid. J Cell Physiol 164:424-433.
50. Zhang P, Wong C, Liu D, Finegold M, Harper JW, Elledge SJ. 1999. p21(CIP1) and p57(KIP2) control muscle differentiation at the myogenin step. Genes Dev 13:213-224.